Neurometabolic Disease, Paediatric Neurology
Read Time: 2 mins

Efficient Investigation and Differential Diagnosis of Childhood Onset Niemann-Pick Type C

Copy Link
Published Online: Jun 27th 2012 European Neurological Review, 2012;7(3):153-9 DOI:
Authors: Alasdair Parker
Quick Links:
Article Information

Niemann-Pick disease type C (NPC) is a fatal, neurodegenerative, lysosomal storage disorder. It is rare with a broad phenotypic spectrum and variable age of onset. This complicates diagnosis, which is often delayed by several years after presentation of the first symptoms. It is a treatable condition if detected early, therefore reliable means of diagnosis are essential. Clinical diagnosis of NPC involves identifying characteristic neurological features, taking a detailed history of the patient’s details, and must be confirmed by biochemical and/or genetic testing. The key laboratory diagnostic test for NPC is filipin staining of cultured skin fibroblasts, which shows free cholesterol accumulation in lysosomes resulting from impaired intracellular cholesterol transport. Genetic testing for mutations in the NPC1 and NPC2 genes is also important for confirmation of the diagnosis. However, there is an unmet need for cheaper diagnostic tests with greater specificity and sensitivity.


Filipin, lysosomal storage disorder, Niemann-Pick type C (NPC), NPC1, NPC2, progressive intellectual, neurological deterioration, genetic analysis


Niemann-Pick disease type C (NPC) is a rare, autosomal recessive, neurodegenerative disorder occurring in all ethnic groups, with an estimated minimal incidence of 0.82 per 100,000 live births.1 This figure is likely to be an underestimation due to failure to recognise the clinical characteristics and initiate appropriate tests. NPC is a devastating disorder, characterised by a variety of progressive and disabling neurological/psychiatric symptoms and leading to premature death.2 In the terminal phase, patients are immobile and require tube feeding.3 The emotional and economic burden imposed by NPC on patients, families and society is disproportionate to the rarity of the disease.3

The wide clinical spectrum of NPC was not recognised until the early 1990s, particularly regarding rapidly fatal cases in infants, and no specific laboratory tests had been available making accurate diagnosis challenging. Delayed presentation of NPC in adolescents and adults has further added to the misdiagnosis of this disorder. Since awareness of the disease and diagnostic techniques have improved, what was once considered to be a childhood condition is now increasingly recognised as an illness affecting individuals of all ages.

The biochemistry behind NPC was elucidated in 1984 following studies on cholesterol metabolism.4 It is a cellular lipid trafficking disorder characterised by lysosomal accumulation of low-density lipoprotein (LDL)-derived, unesterified cholesterol.1 Genetic studies found that mutations in two genes, NPC1 (reported in 90–95 % of patients) and NPC2 (~5 % of patients), play a role in the disrupted transport of unesterified cholesterol, sphingolipids and glycosphingolipids. When there is mutation within one of these genes, accumulation of cholesterol in late endosomes and lysosomes within the spleen, liver and brain occurs.3,5,6

NPC is a heterogeneous condition with an age at onset ranging from the perinatal period to as late as 50 years of age or older; juvenile onset (ages 6–15 years) is the most common.1 The age of onset has a major impact on the severity and the course of the disease although progression is linear and independent of this variable (see Figure 1).2,7 The different ages of disease onset can be used to define the disorder: the generally accepted categories are pre/perinatal, early-infantile, late-infantile, juvenile, and adolescent/adult.3 Apart from a subset of patients that die at birth, most patients follow a progressive and ultimately fatal neurological disease course. The lifespan of affected individuals can vary from days to years with many dying between 10 and 25 years of age.1

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:

Alasdair Parker is a member of the Niemann-Pick Type C advisory panel for which he receives an honorarium from Actelion. He has also received remuneration from Actelion for developing and running workshops and lectures.


Alasdair Parker, Consultant Paediatric Neurologist, Child Development Centre, Box 107, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK. E:


The publication of this article was funded by Actelion. The views and opinions expressed are those of the author and not necessarily those of Actelion.




  1. Vanier MT, Niemann-Pick disease type C, Orphanet J Rare Dis, 2010;5:16.
  2. Imrie J, Dasgupta S, Besley GT, et al., The natural history of Niemann-Pick disease type C in the UK, J Inherit Metab Dis, 2007;30:51–9.
  3. Wraith JE, Baumgartner MR, Bembi B, et al., Recommendations on the diagnosis and management of Niemann-Pick disease type C, Mol Genet Metab, 2009;98:152–65.
  4. Pentchev PG, Boothe AD, Kruth HS, et al., A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol, J Biol Chem, 1984;259:5784–91.
  5. Sleat DE, Wiseman JA, El-Banna M, et al., Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport, Proc Natl Acad Sci USA, 2004;101:5886 –91.
  6. Kwon HJ, Abi-Mosleh L, Wang ML, et al., Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol, Cell, 2009;137:1213–24.
  7. Yanjanin NM, Velez JI, Gropman A, et al., Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C, Am J Med Genet B Neuropsychiatr Genet, 2010;153B:132–40.
  8. Pineda M, Perez-Poyato MS, O'Callaghan M, et al., Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series, Mol Genet Metab, 2010;99:358–66.
  9. Philippart M, Engel J, Jr., Zimmerman EG, Gelastic cataplexy in Niemann-Pick disease group C and related variants without generalized sphingomyelinase deficiency, Ann Neurol, 1983;14:492–3.
  10. Kovesi TA, Lee J, Shuckett B, et al., Pulmonary infiltration in Niemann-Pick disease type C, J Inherit Metab Dis, 1996;19:792–3.
  11. Nicholson AG, Florio R, Hansell DM, et al., Pulmonary involvement by Niemann-Pick disease. A report of six cases, Histopathology, 2006;48:596–603.
  12. Shin J, Epperson K, Yanjanin NM, et al., Defining natural history: assessment of the ability of college students to aid in characterizing clinical progression of Niemann-Pick disease, type C, PLoS One, 2011;6:e23666.
  13. Schiffmann R, Niemann-Pick disease type C. From bench to bedside, JAMA, 1996;276:561–4.
  14. Imrie J, Wraith JE, Isolated splenomegaly as the presenting feature of Niemann-Pick disease type C, Arch Dis Child, 2001;84:427–9.
  15. Shulman LM, David NJ, Weiner WJ, Psychosis as the initial manifestation of adult-onset Niemann-Pick disease type C, Neurology, 1995;45:1739–43.
  16. Grau AJ, Brandt T, Weisbrod M, et al., Adult Niemann-Pick disease type C mimicking features of multiple sclerosis, J Neurol Neurosurg Psychiatry, 1997;63:552.
  17. Verity C, Winstone AM, Stellitano L, et al., The epidemiology of progressive intellectual and neurological deterioration in childhood, Arch Dis Child, 2010;95:361–4.
  18. Tang Y, Li H, Liu JP, Niemann-Pick Disease Type C: from molecule to clinic, Clin Exp Pharmacol Physiol, 2010;37:132–40.
  19. Patterson MC, Hendriksz CJ, Walterfang M, et al., Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update, Mol Genet Metab, 2012;106:330–44.
  20. Vanier MT, Rodriguez-Lafrasse C, Rousson R, et al., Type C Niemann-Pick disease: spectrum of phenotypic variation in disruption of intracellular LDL-derived cholesterol processing, Biochim Biophys Acta, 1991;1096:328–37.
  21. Millat G, Bailo N, Molinero S, et al., Niemann-Pick C disease: use of denaturing high performance liquid chromatography for the detection of NPC1 and NPC2 genetic variations and impact on management of patients and families, Mol Genet Metab, 2005;86:220–32.
  22. Ries M, Schaefer E, Luhrs T, et al., Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C, J Inherit Metab Dis, 2006;29:647–52.
  23. Tangemo C, Weber D, Theiss S, et al., Niemann-Pick Type C disease: characterizing lipid levels in patients with variant lysosomal cholesterol storage, J Lipid Res, 2011;52:813–25.
  24. Madra M, Sturley SL, Niemann-Pick type C pathogenesis and treatment: from statins to sugars, Clin Lipidol, 2010;5:387–95.
  25. Patterson MC, Vecchio D, Jacklin E, et al., Long-term miglustat therapy in children with Niemann-Pick disease type C, J Child Neurol, 2010;25:300–5.
  26. Patterson MC, Vecchio D, Prady H, et al., Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study, Lancet Neurol, 2007;6:765–72.
  27. Rosenbaum AI, Maxfield FR, Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches, J Neurochem, 2011;116:789–95.
  28. Gelsthorpe ME, Baumann N, Millard E, et al., Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding, J Biol Chem, 2008;283:8229–36.
  29. Patterson MC, Platt F, Therapy of Niemann-Pick disease, type C, Biochim Biophys Acta, 2004;1685:77–82.
  30. Ramirez CM, Liu B, Taylor AM, et al., Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life, Pediatr Res, 2010;68:309–15.
  31. Davidson CD, Ali NF, Micsenyi MC, et al., Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression, PLoS One, 2009;4:e6951.
  32. Pipalia NH, Cosner CC, Huang A, et al., Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts, Proc Natl Acad Sci U S A, 2011;108:5620–5.
  33. Jiang X, Sidhu R, Porter FD, et al., A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma, J Lipid Res, 2011;52:1435–45.
  34. Zhang J, Absence of cholesterol biosynthesis and exogenous uptake does not prevent induction of a Niemann-Pick C1 phenotype in normal cells, 2009. Available at: JinzhiZhang.doc (accessed 29 March 2012).

Further Resources

Share this Article
Related Content In Paediatric Neurology
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72